TFG Advisers’s DexCom DXCM Stock Holding History

TFG Advisers’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,388	Closed	-$75K	–	228
2019 Q4	$75K	Buy	+1,388	New	+$65.8K	0.04%	242

Other funds holding DXCM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

TFG Advisers's DXCM Position: Q1 2020 in Review

TFG Advisers sold out of DexCom (DXCM) in Q1 2020, closing a stake of 1,388 shares — an estimated $75K sold.

TFG Advisers first reported a position in DXCM in Q4 2019 and held it in 1 quarter. The position peaked at $75K in Q4 2019. 593 funds tracked by Wall St. Rank hold DXCM as of Q1 2020.

TFG Advisers reported no remaining DexCom position as of Q1 2020 after selling out during the quarter.
TFG Advisers sold 1,388 DexCom shares in Q1 2020, an estimated $75K.
TFG Advisers first reported a position in DexCom in Q4 2019 and held it in 1 quarter.
TFG Advisers's DexCom position peaked at $75K in Q4 2019.
593 funds tracked by Wall St. Rank held DexCom as of Q1 2020.

Based on TFG Advisers's 13F filing for Q1 2020, filed 24 Apr 2020.